Therabron Compound Secures Fast Track Status

The FDA has granted fast track status to Therabron Therapeutics’ CG100 to prevent chronic lung disease associated with premature birth.

The compound CG100 is based on the recombinant human Club Cell 10 kDa protein rhCC10’s CG100 component. The compound currently is in Phase 2 trials. The Maryland startup specializes in respiratory and fibrotic conditions and currently has three other drugs in development.